MS vs PFE: Which Is the Better Buy?
Side-by-side comparison of Morgan Stanley and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Morgan Stanley · Financial Services
$206.27
+15.9% upside to fair value
Med Conviction
Grade C
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
MS has more upside to fair value
(+15.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MS |
PFE |
| Current Price |
$206.27 |
$27.64 |
| Fair Value Estimate |
$239.00 |
$30.94 |
| Upside to Fair Value |
+15.9%
|
+12.0%
|
| Market Cap |
$325.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
23.5x
|
17.4x
|
| Price / Sales |
2.6x
|
2.5x
|
| Price / FCF |
—
|
14.3x
|
| Revenue Growth YoY |
+22.4%
|
+2.6%
|
| Gross Margin |
59.7%
|
71.3%
|
| Operating Margin |
20.7%
|
25.1%
|
| Return on Equity |
18.1%
|
4.9%
|
| Dividend Yield |
2.01% |
6.22% |
| FCF Yield |
—
|
6.97%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Morgan Stanley is a diversified capital-markets and wealth-management franchise spanning institutional securities, advisor-led and self-directed wealth, workplace services, and investment management. Business quality is solid but inherently cyclical: it combines $8.084 trillion of wealth client assets and $2.004 trillion of investment-management AUM/AUS with a strengthening 15.5% institutional pe…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
MS |
PFE |
| Zone Low |
$179.25 |
$23.21 |
| Zone High |
$203.15 |
$26.30 |
| In Buy Zone? |
No
|
No
|